Application of Bacteroides fragilis in the preparation of drugs for treating optic nerve damage

By delivering Bacteroides fragilis and its gene-edited variants into the gastrointestinal tract, the problems of protecting retinal ganglion cells and visual function in glaucoma have been solved, achieving the repair of retinal damage and the suppression of inflammation, thus providing an effective treatment for glaucoma.

CN121221648BActive Publication Date: 2026-03-06SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
2 Cites 0 Cited by

Patent Information

Application Number
CN202510854328.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-06-24
Publication Date
2026-03-06
Estimated Expiration
2045-06-24

AI Technical Summary

Technical Problem

Current technologies have failed to effectively utilize the role of gut microbiota in glaucoma treatment, especially in terms of protecting retinal ganglion cells, protecting visual function, inhibiting microglial cell activation, and activating retinal inflammatory pathways and expressing inflammatory mediators.

Method used

Using Bacteroides fragilis and its gene-edited variants as active ingredients, this product is delivered to the gastrointestinal tract to inhibit retinal microglia activation, reduce retinal ganglion cell loss, maintain retinal nerve fiber layer thickness, improve visual function, and inhibit retinal inflammatory pathway activation and inflammatory mediator expression.

Benefits of technology

Bacteroides fragilis significantly reduces retinal ganglion cell loss, maintains retinal nerve fiber layer thickness, improves visual function, inhibits retinal microglia activation and inflammatory mediator expression, and provides an effective treatment for glaucoma.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A microorganism containing Bacteroides fragilis genes is used as an active ingredient in the preparation of pharmaceuticals, medical devices, or food for treating optic nerve damage. This delivers Bacteroides fragilis (or its functional components) into the gastrointestinal tract, which helps maintain the number of retinal ganglion cells and the thickness of the retinal nerve fiber layer, inhibits the activation of retinal microglia, inhibits the activation of retinal inflammatory pathways and the expression of inflammatory mediators, thereby protecting visual function.
Need to check novelty before this filing date? Find Prior Art